136 related articles for article (PubMed ID: 15870859)
1. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts.
Airley RE; Phillips RM; Evans AE; Double J; Burger AM; Feibig HH; West CM; Stratford IJ
Int J Oncol; 2005 Jun; 26(6):1477-84. PubMed ID: 15870859
[TBL] [Abstract][Full Text] [Related]
2. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies.
Evans A; Bates V; Troy H; Hewitt S; Holbeck S; Chung YL; Phillips R; Stubbs M; Griffiths J; Airley R
Cancer Chemother Pharmacol; 2008 Mar; 61(3):377-93. PubMed ID: 17520257
[TBL] [Abstract][Full Text] [Related]
3. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.
Airley RE; Loncaster J; Raleigh JA; Harris AL; Davidson SE; Hunter RD; West CM; Stratford IJ
Int J Cancer; 2003 Mar; 104(1):85-91. PubMed ID: 12532423
[TBL] [Abstract][Full Text] [Related]
4. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix.
Airley R; Loncaster J; Davidson S; Bromley M; Roberts S; Patterson A; Hunter R; Stratford I; West C
Clin Cancer Res; 2001 Apr; 7(4):928-34. PubMed ID: 11309343
[TBL] [Abstract][Full Text] [Related]
5. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
[TBL] [Abstract][Full Text] [Related]
6. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?
Cooper R; Sarioğlu S; Sökmen S; Füzün M; Küpelioğlu A; Valentine H; Görken IB; Airley R; West C
Br J Cancer; 2003 Sep; 89(5):870-6. PubMed ID: 12942120
[TBL] [Abstract][Full Text] [Related]
7. Investigation of possible endogenous hypoxia markers in colorectal cancer.
Verstraete M; Debucquoy A; Devos E; Sagaert X; Penninckx F; Begg A; Haustermans K
Int J Radiat Biol; 2013 Jan; 89(1):9-15. PubMed ID: 22852555
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of tumour hypoxia.
Young RJ; Möller A
Methods Mol Biol; 2010; 611():151-9. PubMed ID: 19960329
[TBL] [Abstract][Full Text] [Related]
9. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.
Koda M; Kanczuga-Koda L; Sulkowska M; Surmacz E; Sulkowski S
BMC Cancer; 2010 Jun; 10():320. PubMed ID: 20569445
[TBL] [Abstract][Full Text] [Related]
10. Membranous expression of glucose transporter-1 protein (GLUT-1) in embryonal neoplasms of the central nervous system.
Loda M; Xu X; Pession A; Vortmeyer A; Giangaspero F
Neuropathol Appl Neurobiol; 2000 Feb; 26(1):91-7. PubMed ID: 10736070
[TBL] [Abstract][Full Text] [Related]
11. Measurement of hypoxia using invasive oxygen-sensitive electrode, pimonidazole binding and 18F-FDG uptake in anaemic or erythropoietin-treated mice bearing human glioma xenografts.
Scigliano S; Pinel S; Poussier S; Fouyssac F; Plenat F; Karcher G; Chastagner P
Int J Oncol; 2008 Jan; 32(1):69-77. PubMed ID: 18097544
[TBL] [Abstract][Full Text] [Related]
12. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.
Patterson AV; Williams KJ; Cowen RL; Jaffar M; Telfer BA; Saunders M; Airley R; Honess D; van der Kogel AJ; Wolf CR; Stratford IJ
Gene Ther; 2002 Jul; 9(14):946-54. PubMed ID: 12085243
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: correlation between primary and xenograft tumors.
Stegeman H; Rademakers SE; Span PN; Takes RP; van der Kogel AJ; Kaanders JH; Bussink J
Head Neck; 2014 Sep; 36(9):1288-95. PubMed ID: 24668936
[TBL] [Abstract][Full Text] [Related]
14. Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts.
Yaromina A; Quennet V; Zips D; Meyer S; Shakirin G; Walenta S; Mueller-Klieser W; Baumann M
Int J Radiat Biol; 2009 Nov; 85(11):972-80. PubMed ID: 19895274
[TBL] [Abstract][Full Text] [Related]
15. ERO1α is a novel endogenous marker of hypoxia in human cancer cell lines.
Takei N; Yoneda A; Kosaka M; Sakai-Sawada K; Tamura Y
BMC Cancer; 2019 May; 19(1):510. PubMed ID: 31142270
[TBL] [Abstract][Full Text] [Related]
16. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.
Tian M; Zhang H; Nakasone Y; Mogi K; Endo K
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):5-12. PubMed ID: 14551748
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of anticancer agents, growth and chemosensitivity of human tumour xenografts in a segregating stock of AF nude mice.
Maruo K; Emura R; Ohnishi Y; Endo S; Ueyama Y; Nomura T
Lab Anim; 1991 Oct; 25(4):342-7. PubMed ID: 1753695
[TBL] [Abstract][Full Text] [Related]
18. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies.
Oliver RJ; Woodwards RT; Sloan P; Thakker NS; Stratford IJ; Airley RE
Eur J Cancer; 2004 Mar; 40(4):503-7. PubMed ID: 14962715
[TBL] [Abstract][Full Text] [Related]
20. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
